[On Demand]
100 million Americans suffer from chronic pain, resulting in $625 billion in lost-productivity along with detrimentally affecting the lives of those suffering. Despite the fact that the market for chronic pain treatment is expected to grow to over $100 billion by 2024, very few pharmaceuticals make it to market. Doloromics aims to solve these problems and offer aid to those in need.
Where traditional treatments, such as NSAIDs or opioids, treat the symptoms of pain, our strategy is to target novel ligand-receptor interactions to eliminate pain at its roots. Our team has developed a state-of-the-art interactome algorithm we call DOLOReS, which is capable of identifying all ligand-receptor interactions between two tissue types. Using DOLOReS, we have access to drug target acuity that is unparalleled in the field. Further, the field has for too long relied on animal models for drug target discovery - our model uses exclusively human sensory neural tissue from organ donors.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
The DOLOReS algorithm and identified drug targets
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Chief Executive Officer